Results

1–2 of 2 results for Senescence

Senolytic Candidate UBX1325 for Diabetic Macular Edema: The BEHOLD Phase 2 and ASPIRE Phase 2b Trials
Dante Joseph Pieramici, MD
Annual Meeting Talks
2025
48-Week End of Study Results From BEHOLD Phase 2 Study of UBX1325 in Patients With DME
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2023